» Authors » Jorge Carrillo

Jorge Carrillo

Explore the profile of Jorge Carrillo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 131
Citations 2333
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Usai C, Ainsua-Enrich E, Gales V, Pradenas E, Lorca-Oro C, Tarres-Freixas F, et al.
NPJ Vaccines . 2024 Feb; 9(1):48. PMID: 38413645
Age is associated with reduced efficacy of vaccines and linked to higher risk of severe COVID-19. Here we determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine...
12.
Barajas A, Amengual-Rigo P, Pons-Grifols A, Ortiz R, Carmona O, Urrea V, et al.
J Transl Med . 2024 Jan; 22(1):14. PMID: 38172991
Background: Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process for neoantigens has evolved with...
13.
Avila-Nieto C, Vergara-Alert J, Amengual-Rigo P, Ainsua-Enrich E, Brustolin M, Rodriguez de la Concepcion M, et al.
Front Immunol . 2023 Dec; 14:1291972. PMID: 38124756
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of...
14.
Gokengin D, Noori T, Alemany A, Bienkowski C, Liegon G, Inkaya A, et al.
Lancet Reg Health Eur . 2023 Nov; 34:100738. PMID: 37927439
The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region, especially in the Central and Eastern subregions, are hindered by healthcare disparities, data gaps, and...
15.
Barmada A, Handfield L, Godoy-Tena G, de la Calle-Fabregat C, Ciudad L, Arutyunyan A, et al.
Eur J Immunol . 2023 Oct; 54(1):e2350633. PMID: 37799110
In COVID-19, hyperinflammatory and dysregulated immune responses contribute to severity. Patients with pre-existing autoimmune conditions can therefore be at increased risk of severe COVID-19 and/or associated sequelae, yet SARS-CoV-2 infection...
16.
Raich-Regue D, Tenorio R, de Castro I, Tarres-Freixas F, Sachse M, Perez-Zsolt D, et al.
Biomed Pharmacother . 2023 Jun; 164:114997. PMID: 37311279
The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile....
17.
Ortiz R, Barajas A, Pons-Grifols A, Trinite B, Tarres-Freixas F, Rovirosa C, et al.
Int J Mol Sci . 2023 May; 24(10). PMID: 37240371
Feline leukemia virus (FeLV) is one of the most prevalent infectious diseases in domestic cats. Although different commercial vaccines are available, none of them provides full protection. Thus, efforts to...
18.
Avila-Nieto C, Pedreno-Lopez N, Mitja O, Clotet B, Blanco J, Carrillo J
Front Immunol . 2023 Apr; 14:1126170. PMID: 37090699
Syphilis is a sexually or vertically (mother to fetus) transmitted disease caused by the infection of subspecie (TPA). The incidence of syphilis has increased over the past years despite the...
19.
Sanchez-Moral L, Paul T, Martori C, Font-Diaz J, Sanjurjo L, Aran G, et al.
EBioMedicine . 2023 Apr; 91:104555. PMID: 37054630
Background: Reprogramming of immunosuppressive tumor-associated macrophages (TAMs) presents an attractive therapeutic strategy in cancer. The aim of this study was to explore the role of macrophage CD5L protein in TAM...
20.
Tarres-Freixas F, Aguilar-Gurrieri C, Rodriguez de la Concepcion M, Urrea V, Trinite B, Ortiz R, et al.
NPJ Vaccines . 2023 Apr; 8(1):51. PMID: 37024469
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on...